Axogen, Inc. - Common Stock (AXGN)
16.22
+0.08 (0.50%)
NASDAQ · Last Trade: Aug 28th, 10:14 PM EDT
Detailed Quote
Previous Close | 16.14 |
---|---|
Open | 16.02 |
Bid | 15.64 |
Ask | 16.52 |
Day's Range | 16.00 - 16.54 |
52 Week Range | 9.215 - 21.00 |
Volume | 1,407,943 |
Market Cap | 671.46M |
PE Ratio (TTM) | -162.20 |
EPS (TTM) | -0.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,871,361 |
Chart
About Axogen, Inc. - Common Stock (AXGN)
Axogen Inc is a leading provider of innovative surgical solutions for peripheral nerve repair and regeneration. The company specializes in the development and commercialization of advanced medical technologies designed to support nerve repair procedures, particularly in cases of nerve injuries resulting from trauma, surgery, or other medical conditions. By offering a range of products and services, Axogen aims to improve patient outcomes and enhance the quality of life for individuals suffering from nerve damage. Their solutions include biologically designed grafts and additional support products that facilitate the healing process and promote functional recovery. Read More
News & Press Releases
ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences:
By Axogen, Inc. · Via GlobeNewswire · August 27, 2025
Via Benzinga · August 25, 2025
Via Benzinga · August 25, 2025
FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full-year revenue outlook.
Via Benzinga · August 25, 2025
Why Is Axogen Stock Down 11% In Pre-Market Today?stocktwits.com
Via Stocktwits · August 25, 2025
The FDA's move is largely procedural, says one analyst, but it adds incremental uncertainty.
Via Investor's Business Daily · August 25, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · August 25, 2025
Via Benzinga · August 25, 2025
FDA PDUFA goal date extended by three months
By Axogen, Inc. · Via GlobeNewswire · August 25, 2025
Axogen Inc (AXGN) surpasses Q2 2025 estimates with strong revenue and EPS growth, raises full-year guidance, sparking a 15.8% pre-market stock surge.
Via Chartmill · August 5, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · August 5, 2025
Via Benzinga · August 5, 2025
Raises Full Year Revenue Guidance to at Least 17% Growth or $219 Million
By Axogen, Inc. · Via GlobeNewswire · August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.
By Axogen, Inc. · Via GlobeNewswire · July 29, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
By Axogen, Inc. · Via GlobeNewswire · July 22, 2025
Via Benzinga · June 30, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via Chartmill · June 30, 2025

ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale, board director, chief executive officer, and president, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference, on Wednesday, June 11, 2025, at 2:00 p.m. ET.
By Axogen, Inc. · Via GlobeNewswire · May 28, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · May 8, 2025
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025.
By Axogen, Inc. · Via GlobeNewswire · May 8, 2025
Lindsey Hartley, CPA, appointed as Chief Financial Officer to succeed Nir Naor
By Axogen, Inc. · Via GlobeNewswire · May 8, 2025